Ki67 as a Prognostic Marker in Neuroendocrine Tumours: A Systematic Review of the Literature and Quantitative Synthesis of 5 year Survival Data

#1148

Introduction: The ENETS guidelines classify Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs) according to the histological assessment of tumour mitotic count or Ki67 labelling index (LI) on paraffin-embedded tissue, because proliferation rate has been shown to strongly correlate with prognosis. Since the guidelines were published, Ki67 has been established as the more reproducible measure, and further large case series have been reported.

Aim(s): To systematically review articles which report the prognosis of patients by Ki67 LI. The aim of this study is to improve the ability of clinicians to prognosticate for their patients.

Materials and methods: Medline was searched using the terms 'neuroendocrine' AND 'tumors OR tumours OR tumor OR tumour' AND 'Ki-67 OR Ki67 OR mib1 OR mib-1' AND 'prognosis OR survival OR mortality'. 265 abstracts were identified. Articles were excluded if they described non-human specimens, were non-English language, or were published prior to 2000. Abstracts were reviewed to include only papers that related Ki67 and survival outcome, and exclude those reporting non GEP NETs, sub-groups selected by treatment modality, and small series (<20 cases). 11 papers were identified and included.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cave J

Authors: Richards-Taylor S, Tilley C, Hu J, Pearce N, Armstrong T,

Keywords: GEP-NET, prognosis, Ki67,